Structure–Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The following valpromide (VPD) derivatives were synthesized and their structure–pharmacokinetic relationships explored: ethylbutylacetamide (EBD), methylpentylacetamide (MPD), propylisopropylacetamide (PID), and propylallylacetamide (PAD). In addition, the anticonvulsant activity of these compounds was evaluated and compared to that of VPD, valnoctamide (VCD), and valproic acid (VPA). MPD, the least-branched compound had the largest clearance and shortest half-life of all the amides investigated and was the least active. All other amides had similar pharmacokinetic parameters. Unlike the other amides, PID and VCD did not metabolize to their respective homologous acids and were the most active compounds. Our study showed that these amides need an unsubstituted β position in their aliphatic side chain in order to biotransform to their homologous acids. An amide which is not metabolized is more potent as an anticonvulsant than its biotransformed isomer. All amides were more active than their respective homologous acids. In this particular series of aliphatic amides, which were derived from short-branched fatty acids, the anticonvulsant activity was affected by the pharmacokinetics in general and by the biotransformation of the amide to its homologous acid in particular. This amide–acid biotransformation appeared to be dependent upon the chemical structure, especially upon the substitution at position β of the molecule.
- P. Favel, J. Cartier, J. P. Gratadou, and G. Gratadou. Epilepsia 14:329–334 (1973).
- R. Musolino, G. Gallitto, L. Morgante, F. Pisani, and R. Di Perri. Acta Neurol. 2:107–114 (1980).
- F. Pisani and R. Di Perri. Ital. J. Neurol. Sci. 4:245–249 (1980).
- F. Pisani, A. Fazio, G. Oteri, and R. Di Perri. Ther. Drug Monit. 3:297–301 (1981).
- M. Bialer, A. Rubinstein, I. Raz, and O. Abramsky. Eur. J. Clin. Pharmacol. 27:501–503 (1984).
- R. H. Levy. Epilepsia 25:Suppl. 1 (1984).
- F. Pisani, A. A. D'Agostino, A. Fazio, G. Oteri, G. Primerano, and R. Di Perri. Epilepsia 23:115–121 (1982).
- M. Bialer, A. Rubinstein, J. Dubrovsky, I. Raz, and O. Abramsky. Int. J. Pharm. 23:25–33 (1985).
- W. Loscher and H. Nau. Neuropharmacology 24:427–435 (1985).
- J. W. A. Meijer, C. D. Binnie, R. M. C. Debets, J. A. P. Van Parys, and N. K. B. De Beer-Pawlikowski. Lancet 1:802 (1984).
- G. M. Pacifici, T. Tomson, L. Bertilsson, and A. Rane. Lancet 1:397–398 (1985).
- F. Pisani, A. Fazio, G. Oteri, G. Ruello, C. Gitto, F. Russo, and E. Perucca. Epilepsia 27:548–552 (1986).
- G. M. Pacifici and A. Rane. Pharmacol. Toxicol. 60:237–238 (1987).
- F. Pisani, A. Fazio, G. Oteri, E. Spina, E. Perucca, and L. Bertilsson. Br. J. Clin. Pharmacol. 25:611–613 (1988).
- M. Bialer and A. Rubinstein. J. Pharm. Pharmacol. 35:607–609 (1983).
- M. Bialer and A. Rubinstein. Biopharm. Drug Dispos. 5:177–183 (1984).
- W. Stepansky. Curr. Ther. Res. 2:144–149 (1960).
- _Merck. The Merck Index, 10th ed., Merck, Rahway, N.J., 1983, p. 1417.
- Martindale. The Extra Pharmacopoeia, 28th ed., Pharmaceutical Press, London, 1982, p. 1563.
- A. Haj-Yehia and M. Bialer. J. Pharm. Sci. 77:831–834 (1988).
- F. De Matteis. Drug Metab. Dispos. 1:267–275 (1973).
- P. R. Oritz de Montellano and B. A. Mico. Annu. Rev. Pharmacol. Toxicol. 23:481–503 (1983).
- P. E. Keane, J. Simiand, E. Mendes, V. Santucci, and M. Morre. Neuropharmacology 22:875–879 (1983).
- R. J. Porter, J. J. Cereghino, G. D. Gladding, B. J. Hessie, H. J. Kupferberg, B. Scoville, and B. G. White. Cliv. Clin. Q. 51:293–305 (1984).
- M. Bialer, M. Friedman, and A. Rubinstein. J. Pharm. Sci. 73:991–993 (1984).
- M. Bialer and B. Hoch. J. Chromatogr. Biomed. Appl. 337:408–411 (1985).
- M. Gibaldi and D. Perrier. Pharmacokinetics, Ed. 2, Marcel Dekker, New York, 1982, pp. 445–449.
- M. Gibaldi and D. Perrier. Pharmacokinetics, Ed. 2, Marcel Dekker, New York, 1982, pp. 409–417.
- L. Z. Benet and R. L. Galeazzi. J. Pharm. Sci. 68:1071–1074 (1979).
- K. Yamaoka, T. Nakagawa, and T. Uno. J. Pharmacokinet. Biopharm. 6:547–588 (1978).
- S. A. Kaplan, M. L. Jack, S. Cotler, and K. Alexander. J. Pharmacokinet. Biopharm. 1:201–212 (1973).
- M. Rowland and T. Tozer. Clinical Pharmacokinetics, Lea and Febiger, Philadelphia, 1980, pp. 124–132.
- K. Yamaoka. Methods for Pharmacokinetic Analysis for Personal Computers, Ed. 2, Nanko-D Ltd., Tokyo, 1986, pp. 145–175.
- M. Rowland and T. Tozer. Clinical Pharmacokinetics, Lea and Febiger, Philadelphia, 1980, pp. 48–52.
- M. Gibaldi and D. Perrier. Pharmacokinetics, Ed. 2, Marcel Dekker, New York, 1982, pp. 327–330.
- P. L. Altman and D. S. Dittmer. Biological Data Book, Ed. 2, Vol. III, Federation of American Societies for Experimental Biology, Bethesda, Md., 1974, pp. 1072–1710.
- G. R. Wilkinson and D. G. Sland. Clin. Pharmacol. Ther. 18:337–380 (1975).
- Structure–Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity
Volume 6, Issue 8 , pp 683-689
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- valproic acid
- antiepileptic activity
- Industry Sectors